Market capitalization | CHF4.22b |
Enterprise Value | CHF4.67b |
P/E (TTM) P/E ratio | 26.14 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.61 |
P/S ratio (TTM) P/S ratio | 3.26 |
P/B ratio (TTM) P/B ratio | 4.30 |
Revenue growth (TTM) Revenue growth | 1.82% |
Revenue (TTM) Revenue | CHF1.29b |
As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.
14 Analysts have issued a Siegfried Holding forecast:
14 Analysts have issued a Siegfried Holding forecast:
Dec '24 |
+/-
%
|
||
Revenue | 1,295 1,295 |
2%
2%
|
|
Gross Profit | 329 329 |
3%
3%
|
|
EBITDA | 274 274 |
10%
10%
|
EBIT (Operating Income) EBIT | 190 190 |
13%
13%
|
Net Profit | 160 160 |
42%
42%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Siegfried Holding AG engages in the development and manufacture of active pharmaceutical ingredients for pharmaceutical clients with research and development programs, related intermediates, and controlled substances. It also provides development and production services for finished dosage forms including sterile filling. The company was founded by Samuel Benoni Siegfried in 1873 and is headquartered in Zofingen, Switzerland.
Head office | Switzerland |
CEO | Marcel Imwinkelried |
Employees | 3,886 |
Founded | 1873 |
Website | www.siegfried.ch |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.